AR114938A1 - EXPRESSION VARIANTS OF CDKL5 AND FUSION PROTEINS CDKL5 - Google Patents

EXPRESSION VARIANTS OF CDKL5 AND FUSION PROTEINS CDKL5

Info

Publication number
AR114938A1
AR114938A1 ARP180103526A ARP180103526A AR114938A1 AR 114938 A1 AR114938 A1 AR 114938A1 AR P180103526 A ARP180103526 A AR P180103526A AR P180103526 A ARP180103526 A AR P180103526A AR 114938 A1 AR114938 A1 AR 114938A1
Authority
AR
Argentina
Prior art keywords
cdkl5
fusion proteins
variants
polypeptides
expression variants
Prior art date
Application number
ARP180103526A
Other languages
Spanish (es)
Inventor
Sean Clark
Original Assignee
Amicus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc
Publication of AR114938A1 publication Critical patent/AR114938A1/en

Links

Abstract

Variantes de la enzima CDKL5, y proteínas de fusión que comprenden polipéptidos CDKL5 de longitud completa o variantes de CDKL5. Dichas proteínas de fusión pueden incluir polipéptidos penetradores de células y opcionalmente comprenden polipéptidos de señales directrices y/o marcas. También se proveen métodos para producir dichas variantes y proteínas de fusión CDKL5, así como composiciones farmacéuticas, métodos de tratamiento y usos de dichas proteínas recombinantes.Variants of the CDKL5 enzyme, and fusion proteins comprising full-length CDKL5 polypeptides or CDKL5 variants. Such fusion proteins can include cell-penetrating polypeptides and optionally comprise leader and / or tag polypeptides. Methods for producing said CDKL5 fusion proteins and variants are also provided, as well as pharmaceutical compositions, treatment methods and uses of said recombinant proteins.

ARP180103526A 2017-11-30 2018-12-03 EXPRESSION VARIANTS OF CDKL5 AND FUSION PROTEINS CDKL5 AR114938A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762592936P 2017-11-30 2017-11-30

Publications (1)

Publication Number Publication Date
AR114938A1 true AR114938A1 (en) 2020-11-11

Family

ID=73543378

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180103526A AR114938A1 (en) 2017-11-30 2018-12-03 EXPRESSION VARIANTS OF CDKL5 AND FUSION PROTEINS CDKL5

Country Status (1)

Country Link
AR (1) AR114938A1 (en)

Similar Documents

Publication Publication Date Title
CL2022000036A1 (en) Modified polypeptides and uses thereof (divisional application no. 201900261)
CY1124309T1 (en) MODIFIED FGF-21 POLYPEPTIDES AND USES THEREOF
PH12018502361A1 (en) Gdf15 fusion proteins and uses thereof
CL2020000810A1 (en) Fusion proteins comprising enzyme replacement therapy enzymes.
BR112017018975A2 (en) fusion proteins comprising a binding protein and an interleukin-15 polypeptide having a reduced affinity for il15ra and therapeutic uses thereof.
MX2018007145A (en) Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use.
BR112017006736A2 (en) antimostatin antibodies, polypeptides containing variant fc regions, and methods of use
CL2019002132A1 (en) Modified relaxin polypeptides comprising a pharmacokinetic enhancer and their uses.
PH12020550927A1 (en) Therapeutic enzyme fusion protein having novel structure and use thereof
ES2694667T3 (en) Method for producing oxalate oxidases having optical activity near physiological pH and use of such recombinant oxalate oxidases in the treatment of oxalate-related diseases
MX2020005670A (en) Cdkl5 expression variants and cdkl5 fusion proteins.
CY1124727T1 (en) TATK-CDKL5 FUSION PROTEINS, COMPOSITIONS, PHARMACEUTICAL FORMS AND THEIR USE
PE20151774A1 (en) CONSTRUCTIONS OF MITOCHONDRIAL PROTEINS AND THEIR USES
CL2020000733A1 (en) Fusion protein comprising a portion of fgf-18.
EA201790178A1 (en) PEPTIDES BEARING MANNOSE-6-PHOSPHATE, FUSED WITH LIZOSOMAL ENZYME
EA202090084A1 (en) NEW THERAPEUTIC ENZYME Fusion PROTEIN AND ITS APPLICATION
EA201691532A1 (en) SUPEREXPRESSION OF REGULATORS OF THE PATH OF N-GLYCOSYLATION FOR MODULATION OF GLYCOSILATION OF RECOMBINANT PROTEINS
MX2018010196A (en) Targeted therapeutic lysosomal enzyme fusion proteins, associated formulations and uses thereof.
PE20190966A1 (en) FACTOR VIII ADDRESSED TO RED BALLOONS AND METHOD FOR USE
WO2014150748A3 (en) Stabilized single human cd4 domains and fusion proteins
BR112015029145A2 (en) USES OF A FIBROBLAST GROWTH FACTOR 1 (FGFR1) RECEPTOR EXTRACELLULAR DOMAIN (ECD) AND PATIENT IDENTIFICATION METHODS
MX2018003445A (en) Expression of fc-containing proteins.
AR114938A1 (en) EXPRESSION VARIANTS OF CDKL5 AND FUSION PROTEINS CDKL5
ECSP22049014A (en) PROGRANULIN VARIANTS
CR20190389A (en) Factor ix fusion proteins and methods of making and using same